Business Wire12d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd ...
Morningstar12d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...
Cure Today11d
First Patients Dosed in Three Trials Assessing Dato-DXd-Based Regimens in Lung Cancer
Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung cancer. The first patients with locally advanced or metastatic nonsquamous non ...
India Infoline25d
Memorandum of Association: Meaning, Objectives, Clauses and Importance in Company Law
Company law mandates that either a private or public company create a Memorandum of Association (MOA) upon incorporation. When the company is first founded, the petition needs to be filed to the ...
pharmaphorum1d
AZ and Daiichi's TROP2 ADC shows promise in first-line lung cancer
Data from the TROPION-Lung02 reported at the World Congress on Lung Cancer (WCLC) showed an overall response rate of 37% when DS-1062 (datopotamab deruxtecan) was combined with Merck & Co's PD-1 ...
pharmaphorum2d
WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer
MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage ...
National Institute for Health and Care Excellence29d
Awaiting development: Guidance and quality standards
Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845 Technology appraisal guidance Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous ...
BioSpace12d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 expression ...
PipelineReview.com11d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
TOKYO, Japan & BASKING RIDGE, NJ, USA I October 30, 2024 I The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan ...
National Institute for Health and Care Excellence20d
In development: Guidance, quality standards and advice
diagnosis and early management NICE guideline 13 August 2025 Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155] Technology appraisal guidance 20 August 2025 ...
nzgeo.com25d
Moa: The Life and Death of New Zealand’s Legendary Bird
The Moa were perhaps the most unusual family of birds that ever lived. Some boasted legs built like an elephant, others laid eggs the size of rugby balls, and the giant moa was the tallest bird ever ...